Isoflurane Inhalant Product

Phase 3Small molecule

SSunnybrook Health Sciences Centre

Isoflurane Inhalant Product is one of 35 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

Critically Ill PatientsRecruiting

COVID-19Phase 3

Active, not recruiting

Critically Ill PatientsPhase 3

Recruiting

Competition

Competitive Landscape

309 competitors in COVID-19

#DrugCompanyPhaseTrials

Isoflurane Inhalant Product

SSunnybrook Health Sciences Centre

Phase 3

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Calciferol

Activella

Tricor

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Critically Ill Patients

NCT05867472

Q2 2027

Phase 3Active, not recruiting

COVID-19

NCT04415060

Clinical

Trials by Indication[1]

Orthopedic Surgery1 trial

Continuous Versus Single-Shot Spinal Anesthesia for Orthopedic Surgery

Completed·—·N/A·NCT06625606·105 enrolled

Inhalational Anesthesia1 trial

Inhalational Anesthesia vs TIVA in Endoscopic Tympanoplasty

Unknown status·OOur Lady of the Lake Hospital·Phase 1·NCT05993039·100 enrolled

COVID-191 trial

SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival

Active, not recruiting·SSunnybrook Health Sciences Centre·Phase 3·NCT04415060·800 enrolled

Critically Ill Patients1 trial

Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents

Recruiting·SSunnybrook Health Sciences Centre·Phase 3·NCT05867472·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Isoflurane Inhalant Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isoflurane Inhalant Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isoflurane Inhalant Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunnybrook Health Sciences Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSunnybrook Health Sciences Centre

Isoflurane Inhalant Product

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Orthopedic Surgery1 trial

Inhalational Anesthesia1 trial

COVID-191 trial

Critically Ill Patients1 trial

References

Drug Info

Quick Facts

Related News